Immunomedics Inc. this week settled a patent infringement suit against Cytogen Corp. and C.R. Bard Inc. for an undisclosed payment and without any admission of fault or liability.
Immunomedics filed suit on Feb. 17, 2000, alleging that use of Cytogen's ProstaScint product infringed U.S. Patent No. 4,460,559, which claims a method for detecting and localizing tumors.
Immunomedics is a biopharmaceutical company focused on the development, manufacture and commercialization of diagnostic imaging and therapeutic products for the detection and treatment of cancer and other serious diseases.